ArticleCancer diagnosis & prognosis
MRS Imaging as Complement to MRI in the Post-treatment Follow-up of Glial Brain Tumors.
Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aim: Central nervous system tumors have a very low incidence worldwide. However, they represent a significant cause of mortality and morbidity. Magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS) and magnetic resonance spectroscopy imaging (MRSI) techniques provide metabolic information complementary to anatomical alterations. The aim of this study was to characterize different metabolic patterns and determine treatment outcomes in glial brain tumors. Patients and Methods: Forty-four previously treated patients participated in this prospective study, including 20 cases of low-grade (LG) and 24 high-grade (HG), gliomas. All patients underwent conventional MRI combined with MRS and MRSI using a 1.5 Tesla (T) magnet. Results: Distinct metabolic profiles were observed via MRS and MRSI compared to normal brain tissue. Among the LG tumors, 10 remained stable with mean choline (Cho)/ N-Acetyl Aspartate (NAA) and NAA/creatine (Cr) ratios of 1.49 ( Conclusion: MRS and MRSI provide valuable metabolic information that complements MRI in the post-treatment evaluation of glial brain tumors. These techniques enhance the detection of tumor recurrence, progression, and radiation necrosis, thereby supporting clinical decision-making and optimizing patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.